Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

TFG-001

Source date not recordedAnalyse record ↗

Preclinical iPSC-derived dopaminergic microtissue designed to replace lost neurons and reinnervate host striatal circuitry in Parkinson's disease.

Modality
transplantable iPSC-derived 3D dopaminergic neural microtissue containing mature neurons and progenitors
Availability (US)
Preclinical; a first-in-human clinical-trial application is targeted for 2027 and no human trial is active
Biomarkers
dopamine release; graft survival and maturation; axonal reinnervation; synaptic integration; motor outcomes in preclinical models
Hallmark targeted
stem-cell exhaustion, regenerative decline, altered intercellular communication
Kind
investigational cell therapy